# SARS-CoV-2 Spike glycoprotein [mRNA]

## Pfizer-BioNTech (5-11y/o) 0.2mL/dose (1.3mL/vial)

| TAH Drug Code      | [IBNT1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IBNT1)                                                                              |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 5 through 11 Years of Age                                 |
| Dosing             | IM， 0.2 mL， 5-11 years old， 2-dose series separated by at least 3 weeks                                                                          |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                       |
| Contraindications  | Hypersensitivity to the active substance or to any of the excipients.                                                                               |
| Adverse Effects    | erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea. |
| Pregnancy          | Unknown                                                                                                                                             |
| Lactation          | Unknown                                                                                                                                             |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                 |

## Pfizer-BioNTech (6M-4歲) 0.2mL/dose (0.4mL/vial)

| TAH Drug Code      | [IBNT6M](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IBNT6M)                                                                                                                                                                                                                           |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 6 months to 4 Years of Age                                                                                                                                                                               |
| Dosing             | 6 months to 4 years: Primary series， 0.2 mL IM for 2 doses， administered 3 weeks apart， followed by a third dose (0.2 mL) administered at least 8 weeks after the second dose.                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                      |
| Contraindications  | Hypersensitivity to the active substance or to any of the excipients.                                                                                                                                                                                                                              |
| Adverse Effects    | Common Dermatologic: Erythema at injection site， Injection site pain， Swelling at injection site. Musculoskeletal: Arthralgia， Myalgia. Neurologic: Headache. Other: Fatigue， Fever， Shivering. Serious Gastrointestinal: Appendicitis. Immunologic: Anaphylaxis， Hypersensitivity reaction. |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                            |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                            |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                                                                                                                                |

## COVID-19 Vaccine JN.1 0.5mL/dose

| TAH Drug Code      | [ICOJN](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOJN)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Indicated for active immunization in children over 6 months， adolescents， and adults to prevent COVID-19.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Adults and 12 years and older: 0.5 mL IM as a single dose; if previously vaccinated with any COVID-19 vaccine， administer at least 6 months after the last dose of COVID-19 vaccine. 5-11 years: 0.25 mL IM as a single dose; if previously vaccinated with any COVID-19 vaccine， administer at least 6 months after the last dose of COVID-19 vaccine. 6 months through 4 years: (No previous COVID-19 vaccine) 0.25 mL IM for 2 doses administered 28 days apart. (Previously vaccinated with 1 dose of any Moderna COVID-19 vaccine) 0.25 mL IM as a single dose; administer at least 28 days after receipt of previous dose. (Previously vaccinated with 2 dose of any Moderna COVID-19 vaccine or have a known history of SARS-CoV-2 infection) 0.25 mL IM as a single dose; administer at least 6 months after receipt of previous dose.                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Known history of severe allergic reactions (eg， anaphylaxis) to any component of the Moderna COVID-19 vaccine (inactive ingredients include tromethamine， acetic acid， sodium acetate， sucrose， cholesterol， distearoylphosphatidylcholine [ie， DSPC]， and polyethylene glycol [ie， PEG2000-DMG]) or severe allergic reaction following a previous dose of a Moderna COVID-19 vaccine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Common: Erythema at injection site (Adult， 2.1-9% ; adolescent， 9-19.5% ; pediatric， 3.5-18.7%)， Injection site pain (Adult， 67.1-89.9% ; adolescent， 90.6-93.1% ; pediatric， 37.4-94.8%)， Swelling at injection site (Adult， 2.6-12.7% ; adolescent， 13.3-20.5% ; pediatric， 2.8-17%)， Nausea and vomiting (Adult， 5.2-21.4%; adolescent， 11.3-23.9% ; pediatric， 4-24%)， Axillary lymphadenopathy， Tenderness (Adult， 5.3-24.8% ; adolescent， 21-27.8% ; pediatric， 4-27.7%)， Arthralgia (Adult， 16.4-45.6% ; adolescent， 15-28.9% ; pediatric， 6.2-16.1%)， Myalgia (Adult， 19.7-61.7% ; adolescent， 27-46.6% ; pediatric， 9.9-28.2%)， Headache (Adult， 24.5-63%; adolescent， 43.4-70.2% ; pediatric， 11.5-54.3%)， Fatigue (Adult， 33.3-67.8% ; adolescent， 47.9-67.8% ; pediatric， 32-64.5%)， Fever (Adult， 0.3-17.4% ; adolescent， 2.5-12.2% ; pediatric， 3.3-23.9%)， Shivering (Adult， 5.3-48.7% ; adolescent， 18.4-43% ; pediatric， 6.4-48%). Serious: Myocarditis， Pericarditis， Facial swelling， Anaphylaxis， Hypersensitivity reaction (0.3-4.3%). |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## BA1雙價Moderna(Covid19) 0.5mL/dose(2.5mL/vial)

| TAH Drug Code      | [ICOMDBA1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOMDBA1)                                                                                                                                                       |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderna COVID-19 Vaccine， for active immunization to prevent COVID-19 in individuals 18 years of age and older.                                                                                                                   |
| Dosing             | IM， 0.5 mL， > or = 18 years， As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine， bivalent Original/Omicron BA.1 which contains elasomeran and an additional mRNA molecule. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                      |
| Contraindications  | Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g.， anaphylaxis) to any component of the Moderna COVID-19 Vaccine.                                            |
| Adverse Effects    | erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.                                                                                |
| Pregnancy          | Unknown                                                                                                                                                                                                                            |
| Lactation          | Unknown                                                                                                                                                                                                                            |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                                                                |

## BA4/5次世代Moderna(Covid19) 0.5mL/dose(2.5mL/vial)

| TAH Drug Code      | [ICOMDBA5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOMDBA5)                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderna COVID-19 Vaccine， for active immunization to prevent COVID-19 in individuals 18 years of age and older.                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | IM， 0.5 mL， > or = 12 years， As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine， bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule. IM， 0.25 mL， 6-11 years， As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine， bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | History of a severe allergic reaction (e.g.， anaphylaxis) to any component of the Moderna COVID-19 Vaccine.                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.                                                                                                                                                                                                                                                                                                                   |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                                                                                                                                                                                                                                                                                                   |

## COVID-19 Vaccine BioNTech 0.3mL/dose (0.45mL/vial)

| TAH Drug Code      | [ICOVBNT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOVBNT)                                                                          |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | BioNTech COVID-19 Vaccine， for active immunization to prevent COVID-19 in individuals 12 years of age and older.                                   |
| Dosing             | IM， 0.3 mL， > or = 18 years 2 doses administered 3 weeks apart. (Taiwan CDC suggests 2 doses administered 4 weeks apart.)                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                       |
| Contraindications  | Hypersensitivity to the active substance or to any of the excipients.                                                                               |
| Adverse Effects    | erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea. |
| Pregnancy          | Unknown                                                                                                                                             |
| Lactation          | Unknown                                                                                                                                             |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                 |

## COVID-19 Vaccine Moderna 0.5mL/dose (5mL/vial)

| TAH Drug Code      | [ICOVMDN](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOVMDN)                                                                                                              |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderna COVID-19 Vaccine， for active immunization to prevent COVID-19 in individuals 18 years of age and older.                                                                        |
| Dosing             | IM， 0.5 mL， > or = 18 years 2 doses administered 28 days apart.                                                                                                                       |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                           |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                           |
| Contraindications  | Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g.， anaphylaxis) to any component of the Moderna COVID-19 Vaccine. |
| Adverse Effects    | erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.                                     |
| Pregnancy          | Unknown                                                                                                                                                                                 |
| Lactation          | Unknown                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                     |

## COVID-19 XBB.1.5 0.5mL/dose (2.5mL/vial)

| TAH Drug Code      | [ICOXBB15](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ICOXBB15)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For active immunization in children aged 6 months and above， adolescents， and adults to prevent COVID-19 (severe acute respiratory syndrome coronavirus 2 disease).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | For children aged 6 months to 4 years: (1) No prior COVID-19 vaccination and no known SARS-CoV-2 infection history: Two doses， 0.25 mL (25 micrograms) each， at least 28 days apart. (2) Previously received one dose of any Spikevax vaccine: Single 0.25 mL (25 micrograms) dose， at least 28 days after the previous dose. (3) Previously received two doses of Spikevax or had a SARS-CoV-2 infection: Single 0.25 mL (25 micrograms) dose， at least 3 months after the previous dose. For children aged 5 to 11 years: Single 0.25 mL (25 micrograms) dose， with a minimum 3-month interval if previously vaccinated. For adolescents aged 12 and adults: Single 0.5 mL (50 micrograms) dose， with a minimum 3-month interval if previously vaccinated.                                                                                                                                                                                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Known history of severe allergic reactions (eg， anaphylaxis) to any component of the Moderna COVID-19 vaccine (inactive ingredients include tromethamine， acetic acid， sodium acetate， sucrose， sphingomyelin， cholesterol， distearoylphosphatidylcholine， and polyethylene glycol [ie， PEG2000-DMG]) or severe allergic reaction following a previous dose of a Moderna COVID-19 vaccine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Common: Erythema at injection site (Adult， 2.4-9%; adolescent， 13.5-19.5%; pediatric， 3.5-18.7%)， Injection site pain (Adult， 73.9-89.9%; adolescent， 92.4-93.1%; pediatric， 37.4-94.8%)， Swelling at injection site (Adult， 4.5-12.7%; adolescent， 16.2-20.5%; pediatric， 2.8-17%)， Nausea and vomiting (Adult， 5.2-21.4%; adolescent， 11.3-23.9%; pediatric， 6.8-24%)， Axillary lymphadenopathy， Tenderness (Adult， 6.1-16.2%; adolescent， 21-23.3%; pediatric， 15.5-18%)， Arthralgia (Adult， 16.4-45.6%; adolescent， 15-28.9%; pediatric， 6.2-16.1%)， Myalgia (Adults， 19.7-61.7%; adolescents， 26.9-46.6%; pediatrics， 9.9-28.2%)， Headache (Adult， 24.5-63%; adolescent， 43.4-70.2%; pediatric， 11.5-54.3%)， Fatigue (Adult， 33.3-67.8%; adolescent， 47.9-67.8%; pediatric， 40.1-64.5%)， Fever (Adult， 0.3-17.4%; adolescent， 2.5-12.2%; pediatric， 3.3-23.9%)， Shivering (Adult， 5.3-48.7%; adolescent， 18.4-43%; pediatric， 6.4-30.3%) Serious: Myocarditis， Pericarditis， Facial swelling， Anaphylaxis， Hypersensitivity reaction (1.5-4.3%) |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/sars-cov-2-spike-glycoprotein-[mrna]-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

